{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-060352","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.657345+00:00","generated_at":"2026-05-18T11:45:43.588420+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oruka Therapeutics appoints Laura Sandler as COO, effective July 1, 2025","bullets":["Base salary of $460,000 per year; eligible for annual bonus targeted at 40% of base.","Granted option to purchase 25,000 shares of common stock; vests 25% on first anniversary, then monthly over 36 months.","Severance: 12 months base salary if terminated without cause or for good reason outside change-in-control period.","Within change-in-control period: severance of 1x base salary plus target bonus, plus full equity acceleration.","Sandler previously served as SVP of Operations at Oruka since March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-060352","json":"https://secwatch.observer/filing/0001213900-25-060352.json","markdown":"https://secwatch.observer/filing/0001213900-25-060352.md","text":"https://secwatch.observer/filing/0001213900-25-060352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390025060352/0001213900-25-060352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390025060352/ea0247670-8k_oruka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T11:45:43.588420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}